Journal of Cancer Research and Therapeutics Close
 

Figure 2: Cancer-specific survival for patients with hepatocellular carcinoma. Data 1: programmed death ligand-1 positive compared to programmed death ligand-1 negative in tumor, respectively (P = 0.025; log-rank), and data 2: programmed death 1 positive compared to programmed death 1 negative in tumor-infiltrating lymphocytes, respectively (P = 0.08; log-rank). PD-L1+ = Programmed death ligand-1 positive, PD-L1− = Programmed death ligand-1 negative, PD-1+: Programmed death 1 positive, PD-1− = Programmed death 1 negative

Figure 2: Cancer-specific survival for patients with hepatocellular carcinoma. Data 1: programmed death ligand-1 positive compared to programmed death ligand-1 negative in tumor, respectively (<i>P</i> = 0.025; log-rank), and data 2: programmed death 1 positive compared to programmed death 1 negative in tumor-infiltrating lymphocytes, respectively (<i>P</i> = 0.08; log-rank). PD-L1+ = Programmed death ligand-1 positive, PD-L1− = Programmed death ligand-1 negative, PD-1+: Programmed death 1 positive, PD-1− = Programmed death 1 negative